Insulet Co. (NASDAQ:PODD) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC trimmed its position in Insulet Co. (NASDAQ:PODD - Free Report) by 10.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,689 shares of the medical instruments supplier's stock after selling 19,616 shares during the period. Insulet accounts for about 4.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 2nd biggest holding. Parkman Healthcare Partners LLC owned about 0.23% of Insulet worth $37,168,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Blue Trust Inc. raised its holdings in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Insulet during the second quarter valued at approximately $32,000. Venturi Wealth Management LLC raised its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 81 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its holdings in shares of Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 156 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent analyst reports. UBS Group lifted their price target on Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 target price on the stock. Raymond James boosted their target price on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Finally, Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.27.

Insulet Stock Down 0.2 %

Shares of PODD stock traded down $0.45 on Wednesday, hitting $269.21. The company's stock had a trading volume of 508,664 shares, compared to its average volume of 766,515. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The firm's fifty day moving average price is $245.56 and its 200-day moving average price is $215.53. The stock has a market capitalization of $18.88 billion, a price-to-earnings ratio of 45.74, a P/E/G ratio of 4.07 and a beta of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.